Description

Tirzepatide 40 mg — High-Dose Dual GLP-1 / GIP Agonist for Metabolic Research

Tirzepatide is a synthetic dual agonist peptide designed to activate two key incretin receptors simultaneously: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This 40 mg vial provides a higher peptide quantity per unit for research protocols requiring larger working volumes or extended study durations. Tirzepatide has been extensively studied for its effects on glycemic control, body weight regulation, insulin sensitivity, and cardiometabolic markers.

What It Is

• Class: GLP-1 / GIP dual receptor agonist
• Concept: Combines the appetite-suppressing and insulinotropic effects of GLP-1 activation with the complementary metabolic and adipose-tissue effects of GIP activation into a single molecule.
• Format: Research-grade synthetic peptide supplied as a lyophilized powder.

Proposed Mechanisms (Preclinical)

Incretin Receptor Activation

• Engages GLP-1 receptors on pancreatic β-cells, promoting glucose-dependent insulin secretion.
• Activates GIP receptors, contributing to insulinotropic response and influencing adipose tissue handling.
• Demonstrates extended receptor half-life relative to native incretins, allowing for sustained signaling in research preparations.

Downstream Metabolic Effects

• Investigations into body weight, fat mass, and waist circumference across varying dose ranges.
• Research on HbA1c reduction, fasting glucose, and postprandial glucose excursions.
• Studies of insulin sensitivity and β-cell function in metabolic dysfunction models.
• Examination of lipid profile changes, including triglycerides and cholesterol fractions.

Selected Research Highlights

• Body Composition Studies: Tirzepatide has been investigated for dose-dependent reductions in body weight, with several trials reporting substantial decreases in fat mass and waist circumference.
• Glycemic Control: Research has examined Tirzepatide’s effects on glycemic markers in subjects with type 2 diabetes models, often compared against GLP-1 mono-agonist references.
• Cardiovascular Markers: Studies have explored changes in blood pressure, lipid profile, and other markers associated with cardiometabolic risk.
• Comparative Pharmacology: Investigations have compared dual-agonist activity to single-agonist references for differential effects on satiety, glucose handling, and energy balance.

Chemical & Handling Information

• Type: Synthetic dual-agonist peptide
• Backbone: Modified GIP-based sequence with structural modifications conferring balanced GLP-1 and GIP receptor activity (exact sequence per lot specification)
• Appearance: White to off-white lyophilized powder
• Solubility: Reconstitutes readily in bacteriostatic water or sterile saline for laboratory preparation

Specifications

• Peptide: Tirzepatide
• Amount: 40 mg per vial
• Form: Lyophilized powder
• Purity: ≥99% (HPLC); COA per lot available
• Packaging: Sealed glass vials with rubber stopper and aluminum crimp seal, suitable for standard laboratory handling

Storage & Stability

• Store lyophilized vials in a cool, dry place, protected from light.
• Refrigeration or freezing of the lyophilized peptide is recommended for extended stability, in accordance with standard laboratory SOPs.
• After reconstitution, store at 2–8 °C for short-term laboratory use (typically up to 30 days).
• For long-term storage of reconstituted material, aliquot and freeze at −20 °C or below.
• Avoid repeated freeze-thaw cycles, which can degrade peptide integrity.

Research Use Disclaimer

This product is sold strictly for laboratory research use only. Not intended for human or animal consumption. Not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease or condition. Customers are solely responsible for the lawful handling, storage, and use of this product in accordance with all applicable laws and regulations.